Company Description
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.
It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme.
The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds.
Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 126 |
| CEO | Jonathan Lim |
Contact Details
Address: 3115 Merryfield Row, Suite 300 San Diego, California 92121 United States | |
| Phone | 858 465 6511 |
| Website | erasca.com |
Stock Details
| Ticker Symbol | ERAS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001761918 |
| CUSIP Number | 29479A108 |
| ISIN Number | US29479A1088 |
| Employer ID | 83-1217027 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. David M. Chacko M.D. | Chief Financial Officer and Chief Business Officer |
| Ebun S. Garner Esq., J.D. | General Counsel and Corporate Secretary |
| Dr. Michael D. Varney Ph.D. | Chairman of Research and Development, Scientific Advisory Board Member and Director |
| Dr. Nik Chetwyn Ph.D. | Chief Operating Officer |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer |
| Brian L. Baker CPA, M.S. | Senior Vice President of Finance |
| Chandra D. Lovejoy M.S. | Chief Regulatory Affairs Officer |
| Dr. Robert Shoemaker Ph.D. | Senior Vice President of Research |
| Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |